中国临床药理学杂志2018，Vol.34Issue(3)：209-211,3.DOI:10.13699/j.cnki.1001-6821.2018.03.005
瑞舒伐他汀钙片治疗高血压脑出血的临床研究
Clinical trial of rosuvastatin calcium tablets in the treatment of hypertensive cerebral hemorrhage
刘长明 1刘荣2
作者信息
- 1. 唐山工人医院急诊内科,河北 唐山 063000
- 2. 唐山工人医院眼科,河北 唐山 063000
- 折叠
摘要
Abstract
Objective To observe the efficacy and safety of rosuvastatin calcium tablets in the treatment of hypertensive cerebral hemorrhage.Methods A total of 134 patients with hypertensive intracerebral hemorrhage were randomly divided into control group (n =65 cases) and treatment group (n =69 cases).Control group was treated with hemostasis,maintaining blood pressure stability and controlling intracranial pressure and so on.Treatment group was given rosuvastatin 10 mg per time,qd,orally,on the basis of control group.Two groups were treated for 14 days.The clinical efficacy,national institutes of health stroke scale (NIHSS) scores and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of control and control groups were 89.86％ (62 cases/69 cases) and 75.38％ (49 cases/65 cases),the NIHSS scores of control and control groups were (6.63 ±3.36) and (12.37 ±6.84) score,the differences were statistically significant (all P ＜ 0.05).The adverse drug reactions in treatment group were skin rash,joint pain,muscle soreness and gastrointestinal reaction,which in control group were rashes and gastrointestinal reactions.The total incidences of adverse drug reactions of treatment and control groups were 5.80％ and 4.62％ without significant difference (P ＞ 0.05).Conclusion Rosuvastatin calcium tablets have a definitive clinical efficacy in the treatment of hypertensive cerebral hemorrhage,which can improve the functional status of nerve defects,without increasing the incidence of adverse drug reactions.关键词
瑞舒伐他汀钙片/高血压脑出血/安全性Key words
rosuvastatin calcium tablet/hypertensive cerebral hemorrhage/safety分类
医药卫生引用本文复制引用
刘长明,刘荣..瑞舒伐他汀钙片治疗高血压脑出血的临床研究[J].中国临床药理学杂志,2018,34(3):209-211,3.
